Sermorelin mechanism, half-life, and the published corpus — without the bro-science. A founder-operator reading of the GHRH(1-29) literature, including its regulatory record.
Sermorelin is the oldest molecule on the GH-axis page. It predates CJC-1295 by decades. It carries the cleanest regulatory record in the GHRH-analog class and the deepest published corpus. Most of what the founder-operator cohort runs as "GH-axis stack" is built on the mechanistic foundation Sermorelin established.
This page is the working reference. Mechanism, half-life, the corpus, the gaps. The regulatory record is stated as record, not endorsement.
Sermorelin is the synthetic peptide GRF(1-29)NH2 — the first 29 amino acids of human growth hormone-releasing hormone, the active fragment that retains GHRH's GH-releasing activity. It is the parent molecule of the modified GHRH analogs that came later. CJC-1295's "Mod-GRF (1-29)" backbone is a stabilized variant of this same fragment. Tesamorelin is a further-stabilized variant. Sermorelin is the original.
A regulatory note belongs at the top because it shapes how the rest of this page reads. Sermorelin previously held an FDA-approved indication in pediatric growth hormone deficiency, marketed as Geref. The pediatric GHD product was discontinued by the manufacturer; the molecule remains available through compounding pharmacies under prescription in the United States for off-label adult use. This is regulatory record, not an endorsement and not a recommendation. The point of stating it is that Sermorelin sits in a different evidence-and-regulatory tier from the research-only GHRH analogs the founder cohort otherwise discusses.
Sermorelin binds the GHRH receptor on pituitary somatotrophs. Receptor activation drives a cAMP-mediated cascade that triggers GH synthesis and pulsatile release into circulation. From there, GH acts directly on tissue and indirectly through hepatic IGF-1 production. This is the same axis that CJC-1295 and Tesamorelin act on. Sermorelin is the unmodified template.
The foundational mechanism work is from Frohman and colleagues at Northwestern, beginning in the 1980s. Frohman's group characterized human GHRH structure and the activity of the (1-29) fragment, established that the fragment retained full GH-releasing potency, and ran the early human work on GH responses to exogenous administration. Thorner and colleagues at Virginia extended that work into the clinical-physiology picture, including the diagnostic use of GHRH analogs to distinguish hypothalamic from pituitary causes of GH deficiency. These two corpuses — Frohman and Thorner — are the entry points into the published Sermorelin mechanism literature.
The mechanism feature that distinguishes Sermorelin from the modern modified analogs is what made the modifications worth doing. Native GRF(1-29)NH2 is rapidly cleaved at the position-2 amino acid by dipeptidyl peptidase-IV in plasma. CJC-1295's modification protects this cleavage site; the DAC version adds an albumin tether on top. Tesamorelin's modification adds a different N-terminal protection. All three downstream molecules exist because the parent molecule clears too fast to use as a multi-day depot. Sermorelin's short half-life is its design constraint. It is also, depending on the protocol argument, its design feature — pulsatile signaling more closely tracks endogenous GH secretion than depot signaling does.
Sermorelin has a reported plasma half-life on the order of 10 to 20 minutes after subcutaneous administration. This is by an order of magnitude the shortest half-life of any of the GH-axis compounds discussed across this page set.
The short half-life means that Sermorelin produces a brief, sharp GH pulse rather than a sustained elevation. The pulse mimics endogenous secretion in shape — short rise, short fall, return to baseline before the next signaling event. This is the basis of the "pulsatile is closer to physiology" argument that Sermorelin advocates make against the multi-day CJC-1295-with-DAC protocols.
Route in published work is subcutaneous injection. Intravenous administration appears in the diagnostic-testing work. Other routes are not the published norm.
The clinical practice note: because the molecule clears in minutes, the timing of administration relative to other signals — sleep, food, training — is part of what the compounding-pharmacy clinical literature on adult use discusses. We do not address protocol design on this page. The brief handles dosing summaries from cited issue work at the email-gate tier.
Sermorelin sits in a hybrid evidence position. The pediatric GHD work is Tier 1 — randomized, registered, FDA-reviewed. The off-label adult use that the founder-operator cohort actually runs is Tier 4 — small case series, compounding-pharmacy clinical observation, and N=1.
What the published work establishes (Tier 1 — pediatric GHD, regulatory record):
What the published work does not establish at Tier 1:
The Tier 4 adult-use literature is real but small and methodologically uneven. Most of it lives in compounding-pharmacy clinical reports and small open-label series rather than in registered trials.
Sermorelin's community reports are older, calmer, and more clinical-feeling than the CJC and Ipamorelin discussions. The compound has been in adult off-label use long enough that the forum discourse has stabilized.
Sleep architecture changes are the most reported subjective effect. Users describe deeper sleep, sometimes with vivid-dream reports consistent with GH-pulse-related REM effects.
Body composition reports are modest and slow-building rather than dramatic. The pattern reported across multi-month windows is small fat-mass reductions and small lean-mass preservations rather than the larger swings users describe on multi-day-depot protocols. This is consistent with what one would predict from pulsatile versus depot pharmacology.
Recovery and connective-tissue reports are softer than what the BPC-157 / TB-500 cohort describes but appear consistently in the multi-month window in users who pair Sermorelin with training.
PIP reports are low. The molecule has been compounded clinically for long enough that the supply chain is more uniform than the research-peptide GHRH analogs.
We do not have large randomized outcome trials of Sermorelin in healthy adults on body composition, recovery, sleep architecture, or longevity-relevant endpoints. The pediatric GHD trials do not generalize cleanly to the founder-operator cohort.
We do not have head-to-head comparative outcome data against CJC-1295 or against Tesamorelin in healthy adults. The choice between them is being made on mechanism, half-life preference, and supply-chain availability — not on outcome data.
We do not have long-term safety data on sustained adult use over years. The compounding-pharmacy clinical observation base is informative but is not the same evidence type as a registered safety trial.
We do not have a clean answer to whether pulsatile GHRH signaling produces a meaningfully different downstream outcome than depot GHRH signaling on the endpoints the cohort cares about. This is a real open mechanism question and not one the literature has settled.
Issue 1 of The Compound is the GH-axis primer for founder-operators. Sermorelin is the historical anchor of that issue — the molecule the rest of the GH-axis stack is built on top of.
The bigger question for many readers in the cohort right now is lean-mass preservation under GLP-1 administration. GH-axis activation is one of the better-characterized mechanisms for protecting lean mass during caloric deficit, and Sermorelin and Tesamorelin are the GH-axis compounds with the deepest regulatory records and the cleanest mechanistic story. The GLP-1 Muscle Preservation lead magnet on this page is the working reference for that question — what the corpus shows on lean mass under GLP-1 cuts, what the GH-axis adds, and where the literature thins.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound. The pediatric growth hormone deficiency indication referenced above is regulatory record and is not an endorsement.
FTC disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full disclosure on the About page.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators.
[Subscribe — get the GLP-1 Muscle Preservation brief]
What survives Phase 3, what survives the field. The 39% question, decoded.
Download the PDF →